In this context, evaluation of ERBB2 (HER2) alterations is clinically relevant, not only for well-known HER2-driven malignancies like breast or gastric cancer but also for all solid malignancies, as we showed in our cohort analysis. This evidence concerns the gene ERBB2 and gastric cancer.